Trials / Unknown
UnknownNCT02670239
Pharmacokinetics of Imipenem During Ex Vivo Lung Perfusion (EVLP)
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (estimated)
- Sponsor
- University of Turin, Italy · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Ex vivo lung perfusion (EVLP) is an established strategy to evaluate and optimize high-risk donor lungs that would otherwise be rejected for transplantation mainly due to the presence of edema or infection. Extracorporeal circuits may negatively affects pharmacokinetic (PK) of several drugs including antibiotics, thus exposing patients to risk of therapeutic failure or drug toxicity. The investigators set out to examine the concentration of imipenem in lung perfusate and in lung biopsy during EVLP, and its clinical impact.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | normothermic ex vivo lung perfusion |
Timeline
- Start date
- 2014-05-01
- Primary completion
- 2018-01-01
- First posted
- 2016-02-01
- Last updated
- 2016-02-01
Locations
1 site across 1 country: Italy
Source: ClinicalTrials.gov record NCT02670239. Inclusion in this directory is not an endorsement.